Postconditioning and protection from reperfusion injury: Where do we stand: Position Paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology

Cardiovascular Research

Volumn 87, Issue 3, 2010, Pages 406-423

  Ovize, Michel ^a   Baxter, Gary F ^b   Di Lisa, Fabio ^c   Ferdinandy, Péter ^d,e   Garcia Dorado, David ^f   Hausenloy, Derek J ^g   Heusch, Gerd ^h   Vinten Johansen, Jakob ⁱ   Yellon, Derek M ^g   Schulz, Rainer ^h  

^a HOSPICES CIVILS DE LYON   (France)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF PADOVA   (Italy)

^d UNIVERSITY OF SZEGED   (Hungary)

^e UNIVERSITY OF SZEGED   (Hungary)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^h UNIVERSITY OF ESSEN MEDICAL SCHOOL   (Germany)

ⁱ Carlyle Fraser Heart Center   (United States)

Author keywords

Ischaemia; Postconditioning; Reperfusion

Indexed keywords

AUTACOID; CYTOKINE; MITOCHONDRIAL PERMEABILITY TRANSITION PORE; PROTEIN KINASE; CARDIOVASCULAR AGENT;

ACUTE HEART INFARCTION; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; CYTOKINE RELEASE; ENZYME ACTIVATION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE FUNCTION; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; REPERFUSION INJURY; REVIEW; SIGNAL TRANSDUCTION; ALGORITHM; ANIMAL; CARDIOLOGY; EUROPE; EVIDENCE BASED MEDICINE; HEART INFARCTION PREVENTION; HEART MUSCLE; MEDICAL SOCIETY; METABOLISM; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; RISK ASSESSMENT; RISK FACTOR; TREATMENT OUTCOME;

ALGORITHMS; ANIMALS; CARDIOLOGY; CARDIOVASCULAR AGENTS; EUROPE; EVIDENCE-BASED MEDICINE; HUMANS; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; RISK ASSESSMENT; RISK FACTORS; SIGNAL TRANSDUCTION; SOCIETIES, MEDICAL; TREATMENT OUTCOME;

EID: 77954789419     PISSN: 00086363     EISSN: 17553245     Source Type: Journal    
DOI: 10.1093/cvr/cvq129     Document Type: Review

References (221)

1. Page DL, Caulfield JB, Kastor JA, Desanctis RW, Sanders CA. Myocardial changes associated with cardiogenic shock. N Engl J Med 1971;285:133-137.
2. Sobel BE, Bresnahan GF, Shell WE, Yoder RD. Estimation of infarct size in man and its relation to prognosis. Circulation 1972;46:640-648.
3. Burns RJ, Gibbons RJ, Yi Q, Roberts RS, Miller TD, Schaer GL et al. The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysis. J Am Coll Cardiol 2002;39:30-36.
4. Bellandi F, Maioli M, Gallopin M, Toso A, Dabizzi RP. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 2004;62:186-192.
5. Sharpe N, Doughty R. Epidemiology of heart failure and ventricular dysfunction. Lancet 1998;352(Suppl. 1):SI3-SI7. (Pubitemid 28398685)
6. Reimer KA, Lowe JE, Rasmussen MM, Jennings RB. The wavefront phenomenon of ischemic cell death. 1. Myocardial infarct size vs duration of coronary occlusion in dogs. Circulation 1977;56:786-794.
7. Kloner RA, Ganote CE, Jennings RB. The 'no-reflow' phenomenon after temporary coronary occlusion in the dog. J Clin Invest 1974;54:1496-1508.
8. Maroko PR, Libby P, Ginks WR, Bloor CM, Shell WE, Sobel BE et al. Coronary artery reperfusion. I. Early effects on local myocardial function and the extent of myocardial necrosis. J Clin Invest 1972;51:2710-2716.
9. Ginks WR, Sybers HD, Maroko PR, Covell JW, Sobel BE, Ross J Jr. Coronary artery reperfusion. II. Reduction of myocardial infarct size at 1 week after the coronary occlusion. J Clin Invest 1972;51:2717-2723.
10. Chazov EI, Matveeva LS, Mazaev AV, Sargin KE, Sadovskaia GV, Ruda MI. Intracoron-ary administration of fibrinolysin in acute myocardial infarct. Ter Arkh 1976;48:8-19.
11. Rentrop KP, Blanke H, Karsch KR, Wiegand V, Kostering H, Oster H et al. Acute myocardial infarction: intracoronary application of nitroglycerin and streptokinase. Clin Cardiol 1979;2:354-363.
12. DeWood MA, Spores J, Notske R, Mouser LT, Burroughs R, Golden MS et al. Prevalence of total coronary occlusion during the early hours of the transmural myocar-dial infarction. N Engl J Med 1980;303:897-902.
13. Rentrop P, Blanke H. Percutaneous transluminal coronary artery recanalization in evolving myocardial infarction. Cardiovasc Intervent Radiol 1982;5:194-196. (Pubitemid 13238934)
14. Gersh BJ, Stone GW, White HD, Holmes DR Jr. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future? JAMA 2005;293:979-986.
15. Bolli R, Becker L, Gross G, Mentzer R Jr, Balshaw D, Lathrop DA. Myocardial protection at a crossroads. The need for translation into clinical therapy. Circ Res 2004; 95:125-134.
16. Jennings RB, Sommers HM, Smyth GA, Flack HA, Linn H. Myocardial necrosis induced by temporary occlusion of a coronary artery in the dog. Arch Pathol 1960; 70:68-78.
17. Przyklenk K. Lethal myocardial 'reperfusion injury': the opinions of good men. J Thromb Thrombolysis 1997;4:5-6.
18. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985;76:1713-1719.
19. Vinten-Johansen J, Johnston WE, Mills SA, Faust KB, Geisinger KR, DeMasi RJ et al. Reperfusion injury after temporary coronary occlusion. J Thorac Cardiovasc Surg 1988; 95:960-968.
20. Piper HM, Garća-Dorado D, Ovize M. A fresh look at reperfusion injury. Cardiovasc Res 1998;38:291-300.
21. Yellon DM, Hausenloy DJ. Myocardial reperfusion injury. N Engl J Med 2007;357: 1121-1135.
22. Miura T, Miki T. Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy. Basic Res Cardiol 2008;103:501-513.
23. Na HS, Kim YI, Yoon YW, Han HC, Nahm SH, Hong SK. Ventricular premature beat-driven intermittent restoration of coronary blood flow reduces the incidence of reperfusion-induced ventricular fibrillation in a cat model of regional ischemia. Am Heart J 1996;132:78-83.
24. Zhao Z-Q, Corvera JS, Halkos ME, Kerendi F, Wang N-P, Guyton RA et al. Inhibition of myocardial injury by ischemic postconditioning during reperfusion: comparison with ischemic preconditioning. Am J Physiol Heart Circ Physiol 2003;285:H579-H588.
25. Halkos ME, Kerendi F, Corvera JS, Wang NP, Kin H, Payne CS et al. Myocardial protection with postconditioning is not enhanced by ischemic preconditioning. Ann Thorac Surg 2004;78:961-969.
26. Skyschally A, van Caster P, Iliodromitis EK, Schulz R, Kremastinos DT, Heusch G. Ischemic postconditioning\experimental models and protocol algorithms. Basic Res Cardiol 2009;104:469-483.
27. Iliodromitis EK, Downey JM, Heusch G, Kremastinos DT. What is the optimal post-conditioning algorithm? J Cardiovasc Pharmacol Ther 2009;14:269-273.
28. Schaper W, Görge G, Winkler B, Schaper J. The collateral circulation of the heart. Prog Cardiovasc Dis 1988;31:57-77.
29. Shen Y-T, Fallon JT, Iwase M, Vatner SF. Innate protection of baboon myocardium: effects of coronary artery occlusion and reperfusion. Am J Physiol 1996;270: H1812-H1818.
30. Yang XM, Liu Y, Liu Y, Tandon N, Kambayashi J, Downey JM et al. Attenuation of infarction in cynomolgus monkeys: preconditioning and postconditioning. Basic Res Cardiol 2010;105:119-128.
31. Tahk SJ, Choi BJ, Choi SY, Yoon MH, Gwon HC, Hong GR et al. Distal protection device protects microvascular integrity during primary percutaneous intervention in acute myocardial infarction: a prospective, randomized, multicenter trial. Int J Cardiol 2008;123:162-168.
32. Penna C, Tullio F, Merlino A, Moro F, Raimondo S, Rastaldo R et al. Postconditioning cardioprotection against infarct size and post-ischemic systolic dysfunction is influenced by gender. Basic Res Cardiol 2009;104:390-402.
33. Rodriguez-Sinovas A, Cabestrero A, Garcia Del BB, Inserte J, Garcia A, Garcia-Dorado D. Intracoronary acid infusion as an alternative to ischemic postcon-ditioning in pigs. Basic Res Cardiol 2009;104:761-771.
34. Manintveld OC, Te Lintel HM, van den Bos EJ, Suurenbroek GM, Dekkers DH, Verdouw PD et al. Cardiac effects of postconditioning depend critically on the duration of index ischemia. Am J Physiol Heart Circ Physiol 2007;292:H1551- H1560.
35. Kin H, Zhao Z-Q, Sun H-Y, Wang N-P, Corvera JS, Halkos ME et al. Postconditioning attenuates myocardial ischemia/reperfusion injury by inhibiting events in the early minutes of reperfusion. Cardiovasc Res 2004;62:74-85.
36. Philipp S, Downey JM, Cohen MV. Postconditining must be initiated in less than 1 minute following reperfusion and is dependent on adenosine receptors and PI3-kinase. Circulation 2004;110:III-168.
37. Yang X-M, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect hearts by targeting cell signaling pathways. J Am Coll Cardiol 2004;44:1103-1110.
38. Vinten-Johansen J, Yellon DM, Opie LH. Postconditioning. A simple, clinically applicable procedure to improve revascularization in acute myocardial infarction. Circulation 2005;112:2085-2088.
39. Iliodromitis EK, Georgiadis M, Cohen MV, Downey JM, Bofilis E, Kremastinos DT. Protection from postconditioning depends on the number of short ischemic insults in anesthetized pigs. Basic Res Cardiol 2006;101:502-507.
40. Chiari PC, Bienengraeber MW, Pagel PS, Krolikowski JG, Kersten JR, Warltier DC. Isoflurane protects against myocardial infarction during early reperfusion by activation of phosphatidylinositol-3-kinase signal transduction: evidence for anesthetic-induced postconditioning in rabbits. Anesthesiology 2005;102:102-109.
41. Heusch G, Schulz R. Neglect of the coronary circulation: some critical remarks on problems in the translation of cardioprotection. Cardiovasc Res 2009;84:11-14.
42. Kerendi F, Kin H, Halkos ME, Jiang R, Zhao Z-Q, Guyton RA et al. Remote postcon-ditioning. Brief renal ischemia and reperfusion applied before coronary artery reper-fusion reduces myocardial infarct size via endogenous activation of adenosine receptors. Basic Res Cardiol 2005;100:404-412.
43. Liu S, Wu XF, Zhang WZ, Sun YX, Cai SL. Remote postconditioning by brief renal ischemia and reperfusion reduces acute myocardial ischemia and reperfusion induced myocardial apoptosis in rabbits. Zhonghua Xin Xue Guan Bing Za Zhi 2007;35:757-760.
44. Li CM, Zhang XH, Ma XJ, Luo M. Limb ischemic postconditioning protects myocardium from ischemia/reperfusion injury. Scand Cardiovasc J 2006;40:312-317.
45. Gritsopoulos G, Iliodromitis EK, Zoga A, Farmakis D, Demerouti E, Papalois A et al. Remote postconditioning is more potent than classic postconditioning in reducing the infarct size in anesthetized rabbits. Cardiovasc Drugs Ther 2009;23:193-198.
46. Andreka G, Vertesaljai M, Szantho G, Font G, Piroth Z, Fontos G et al. Remote ischaemic postconditioning protects the heart during acute myocardial infarction in pigs. Heart 2007;93:749-752.
47. Dixon IM. Much ado about bone marrow stem cells: role in post-myocardial infarct repair. Cardiovasc Res 2006;71:609-611.
48. Bolli R. Mechanism of myocardial 'stunning'. Circulation 1990;82:723-738.
49. Guth BD, Schulz R, Heusch G. Time course and mechanisms of contractile dysfunction during acute myocardial ischemia. Circulation 1993;87(Suppl. 4):IV-35-IV-42.
50. Tawa M, Fukumoto T, Yamashita N, Ohkita M, Ayajiki K, Okamura T et al. Postcondi-tioning improves postischemic cardiac dysfunction independently of norepinephrine overflow after reperfusion in rat hearts: comparison with preconditioning. J Cardiovasc Pharmacol 2010;55:6-13.
51. Inserte J, Barba I, Hernando V, Garcia-Dorado D. Delayed recovery of intracellular acidosis during reperfusion prevents calpain activation and determines protection in postconditioned myocardium. Cardiovasc Res 2009;81:116-122.
52. Wang G, Zhang S, Joggerst SJ, McPherson J, Zhao DX. Effects of the number and interval of balloon inflations during primary PCI on the extent of myocardial injury in patients with STEMI: does postconditioning exist in real-world practice? J Invasive Cardiol 2009;21:451-455.
53. Mewton N, Croisille P, Gahide G, Rioufol G, Bonnefoy E, Sanchez I et al. Effect of cyclosporine on left ventricular remodeling after reperfused myocardial infarction. J Am Coll Cardiol 2010;55:1200-1205.
54. Galagudza M, Kurapeev D, Minasian S, Valen G, Vaage J. Ischemic postconditioning: brief ischemia during reperfusion converts persistent ventricular fibrillation into regular rhythm. Eur J Cardiothorac Surg 2004;25:1006-1010.
55. Sasaki H, Shimuzu M, Ogawa K, Okazaki F, Taniguchi M, Taniguchi I et al. Brief ischemia/reperfusion performed after prolonged ischemia (ischemic postcondition-ing) can terminate reperfusion arrhythmias with no reduction of cardiac function in rats. Int J Cardiol 2007;48:205-213.
56. Kloner RA, Dow J, Bhandari A. Postconditioning markedly attenuates ventricular arrhythmias after ischemia/reperfusion. J Cardiovasc Pharmacol Ther 2006;11:55-63.
57. Dow J, Bhandari A, Kloner RA. Ischemic postconditioning's benefit on reperfusion ventricular arrhythmias is maintained in the senescent heart. J Cardiovasc Pharmacol Ther 2008;13:141-148.
58. Dow J, Bhandari A, Kloner RA. The mechanism by which ischemic postconditioning reduces reperfusion arrhythmias in rats remains elusive. J Cardiovasc Pharmacol Ther 2009;14:99-103.
59. Zhao H, Sapolsky RM, Steinberg GK. Interrupting reperfusion as a stroke therapy: ischemic postconditioning reduces infarct size after focal ischemia in rats. J Cereb Blood Flow Metab 2006;26:1114-1121.
60. Liu X, Chen H, Zhan B, Xing B, Zhou J, Zhu H et al. Attenuation of reperfusion injury by renal ischemic postconditioning: the role of NO. Biochem Biophys Res Commun 2007;359:628-634.
61. Serviddio G, Romano AD, Gesualdo L, Tamborra R, Di Palma AM, Rollo T et al. Postconditioning is an effective strategy to reduce renal ischaemia/reperfusion injury. Nephrol Dial Transplant 2008;23:1504-1512.
62. Rehni AK, Singh N. Role of phosphoinositide 3-kinase in ischemic postconditioning-induced attenuation of cerebral ischemia-evoked behavioral deficits in mice. Pharmacol Rep 2007;59:192-198.
63. Gao X, Zhang H, Takahashi T, Hsieh J, Liao J, Steinberg GK et al. The Akt signaling pathway contributes to postconditioning's protection against stroke; the protection is associated with the MAPK and PKC pathways. J Neurochem 2008;105:943-955.
64. Pignataro G, Meller R, Inoue K, Ordonez AN, Ashley MD, Xiong Z et al. In vivo and in vitro characterization of a novel neuroprotective strategy for stroke: ischemic postconditioning. J Cereb Blood Flow Metab 2008;28:232-241.
65. Eldaif SM, Deneve JA, Wang NP, Jiang R, Mosunjac M, Mutrie CJ et al. Attenuation of renal ischemia/reperfusion injury by postconditioning involves adenosine receptor and protein kinase C activation. Transpl Int 2010;23:217-226.
66. Deussen A, Möser G, Schrader J. Contribution of coronary endothelial cells to cardiac adenosine production. Pflügers Arch 1986;406:608-614.
67. Faigle M, Seessle J, Zug S, El Kasmi KC, Eltzschig HK. ATP release from vascular endothelia occurs across Cx43 hemichannels and is attenuated during hypoxia. PLoS ONE 2008;3:e2801.
68. Dörge H, Schulz R, Belosjorow S, Post H, van de Sand A, Konietzka I et al. Coronary microembolization: the role of TNFa in contractile dysfunction. J Mol Cell Cardiol 2002;34:51-62.
69. Schulz R, Aker S, Belosjorow S, Heusch G. TNFa in ischemia/reperfusion injury and heart failure. Basic Res Cardiol 2004;99:8-11.
70. Heusch G, Boengler K, Schulz R. Cardioprotection: nitric oxide, protein kinases, and mitochondria. Circulation 2008;118:1915-1919.
71. Granfeldt A, Jiang R, Wang N-P, Mykytenko J, Eldaif S, Deneve J et al. Inhibition of neutrophils is critical to the in vivo cardioprotection of postconditioning. Circulation 2008;118:S403.
72. Shandelya S, Kuppusamy P, Weisfeldt ML, Zweier JL. Evaluation of the role of poly-morphonuclear leukocytes on contractile function in myocardial reperfusion injury. Circulation 1993;87:536-546.
73. 2 radicals in intact hearts with ischemia and reperfu-sion. Am J Physiol Heart Circ Physiol 2003;284:H566-H574.
74. Sun HY, Wang NP, Kerendi F, Halkos M, Kin H, Guyton RA et al. Hypoxic postcon-ditioning reduces cardiomyocyte loss by inhibiting ROS generation and intracellular Ca2+ overload. Am J Physiol Heart Circ Physiol 2005;288:H1900-H1908.
75. Kin H, Wang NP, Mykytenko J, Reeves J, Deneve J, Jiang R et al. Inhibition of myo-cardial apoptosis by postconditioning is associated with attenuation of oxidative stress-mediated nuclear factor-k B translocation and TNF a release. Shock 2008; 29:761-768.
76. Serviddio G, Di Venosa N, Federici A, D'Agostino D, Rollo T, Prigigallo F et al. Brief hypoxia before normoxic reperfusion (postconditioning) protects the heart against ischemia/reperfusion injury by preventing mitochondria peroxyde production and glutathione depletion. FASEB J 2005;19:354-361.
77. Kupai K, Csonka C, Fekete V, Odendaal L, van Rooyen RJ, Marais DW et al. Cholesterol diet-induced hyperlipidemia impairs the cardioprotective effect of postcondi-tioning: role of peroxynitrite. Am J Physiol Heart Circ Physiol 2009;297:H1729-H1735.
78. Schulz R, Rose J, Post H, Heusch G. Involvement of endogenous adenosine in ischae-mic preconditioning in swine. Pflügers Arch 1995;430:273-282.
79. 1 agonist at reperfusion trial (AART): results of a three-center, blinded, randomized, controlled experimental infarct study. Cardiovasc Drugs Ther 2000;14:607-614.
80. Burley DS, Baxter GF. Pharmacological targets revealed by myocardial postcondi-tioning. Curr Opin Pharmacol 2009;9:177-188.
81. Kin H, Zatta AJ, Lofye MT, Amerson BS, Halkos ME, Kerendi F et al. Postconditioning reduces infarct size via adenosine receptor activation by endogenous adenosine. Car-diovasc Res 2005;67:124-133.
82. Donato M, D'Annunzio V, Berg G, Gonzalez G, Schreier L, Morales C et al. Ischemic postconditioning reduces infarct size by activation of A1 receptors and K + (ATP) channels in both normal and hypercholesterolemic rabbits. J Cardiovasc Pharmacol 2007;49:287-292.
83. Xi L, Das A, Zhao ZQ, Merino VF, Bader M, Kukreja RC. Loss of myocardial ischemic postconditioning in adenosine A1 and bradykinin B2 receptors gene knockout mice. Circulation 2008;118:S32-S37.
84. Yang X-M, Philipp S, Downey JM, Cohen MV. Postconditioning's protection is not dependent on circulating blood factors or cells but involves adenosine receptors and requires PI3-kinase and guanylyl cyclase activation. Basic Res Cardiol 2005;100: 57-63.
85. 2b receptor cascade. Car-diovasc Res 2006;70:308-314.
86. Morrison RR, Tan XL, Ledent C, Mustafa SJ, Hofmann PA. Targeted deletion of A2A adenosine receptors attenuates the protective effects of myocardial postcondition-ing. Am J Physiol Heart Circ Physiol 2007;293:H2523-H2529.
87. Xi J, McIntosh R, Shen X, Lee S, Chanoit G, Criswell H et al. Adenosine A2A and A2B receptors work in concert to induce a strong protection against reperfusion injury in rat hearts. J Mol Cell Cardiol 2009;47:684-690.
88. Zatta AJ, Kin H, Yoshishige D, Jiang R, Wang N, Reeves JG et al. Evidence that car-dioprotection by postconditioning involves preservation of myocardial opioid content and selective opioid receptor activation. Am J Physiol Heart Circ Physiol 2008;294:H1444-H1451.
89. Jang Y, Xi J, Wang H, Mueller RA, Norfleet EA, Xu Z. Postconditioning prevents reperfusion injury by activating delta-opioid receptors. Anesthesiology 2008;108: 243-250.
90. Gross ER, Hsu AK, Gross GJ. Opioid-induced cardioprotection occurs via glycogen synthase kinase b inhibition during reperfusion in intact rat hearts. Circ Res 2004;94: 960-966.
91. Chen Z, Li T, Zhang B. Morphine postconditioning protects against reperfusion injury in the isolated rat hearts. J Surg Res 2008;145:287-294.
92. Gross ER, Peart JN, Hsu AK, Auchampach JA, Gross GJ. Extending the cardioprotec-tive window using a novel delta-opioid agonist fentanyl isothiocyanate via the PI3-kinase pathway. Am J Physiol Heart Circ Physiol 2005;288:H2744-H2749.
93. Peart JN, Gross ER, Reichelt ME, Hsu A, Headrick JP, Gross GJ. Activation of kappa-opioid receptors at reperfusion affords cardioprotection in both rat and mouse hearts. Basic Res Cardiol 2008;103:454-463.
94. Baxter GF, Ebrahim Z. Role of bradykinin in preconditioning and protection of the ischaemic myocardium. Brit J Pharmacol 2002;135:843-854.
95. Penna C, Mancardi D, Rastaldo R, Losano G, Pagliaro P. Intermittent activation of bradykinin B(2) receptors and mitochondrial K(ATP) channels trigger cardiac post-conditioning through redox signaling. Cardiovasc Res 2007;75:168-177.
96. Lim SY, Davidson SM, Hausenloy DJ, Yellon DM. Preconditioning and postcondition-ing: the essential role of the mitochondrial permeability transition pore. Cardiovasc Res 2007;75:530-535.
97. Penna C, Mancardi D, Tullio F, Pagliaro P. Postconditioning and intermittent brady-kinin induced cardioprotection require cyclooxygenase activation and prostacyclin release during reperfusion. Basic Res Cardiol 2008;103:368-377.
98. Bell RM, Yellon DM. Bradykinin limits infarction when administered as an adjunct to reperfusion in mouse heart: the role of PI3K, Akt and eNOS. J Mol Cell Cardiol 2003; 35:185-193.
99. Vandenberg JI, Metcalfe JC, Grace AA. Mechanisms of pHi recovery after global ischemia in the perfused heart. Circ Res 1993;72:993-1003.
100. Garcia-Dorado D, Ruiz-Meana M, Piper HM. Lethal reperfusion injury in acute myo-cardial infarction: facts and unresolved issues. Cardiovasc Res 2009;83:165-168.
101. Piper HM, Balser C, Ladilov YV, Schäfer M, Siegmund B, Ruiz-Meana M et al. The role of Na+/H+ exchange in ischemia/reperfusion. Basic Res Cardiol 1996;91:191-202.
102. Ruiz-Maena M, Pina P, Garcia-Dorado D, Rodriguez-Sinovas A, Barba I, Miro-Casa E et al. Glycine protects cardiomyocytes against lethal reoxygenation injury by inhibiting mitochondrial permeability transition. J Physiol 2004;558:873-882.
103. Imahashi K, Kusuoka H, Hashimoto K, Yoshioka J, Yamaguchi H, Nishimura T. Intra-cellular sodium accumulation during ischemia as the substrate for reperfusion injury. Circ Res 1999;84:1401-1406.
104. Theroux P, Chaitman BR, Danchin N, Erhardt L, Meinertz T, Schroeder JS et al. Inhibition of the sodium-hydrogen exchanger with cariporide to prevent myocardial infarction in high-risk ischemic situations. Main results of the GUARDIAN trial. Circulation 2000;102:3032-3038.
105. Heusch G. Postconditioning. Old wine in a new bottle? J Am Coll Cardiol 2004;44: 1111-1112.
106. Cohen MV, Yang XM, Downey JM. The pH hypothesis of postconditioning: staccato reperfusion reintroduces oxygen and perpetuates myocardial acidosis. Circulation 2007;115:1895-1903.
107. Cohen MV, Yang XM, Downey JM. Acidosis, oxygen, and interference with mito-chondrial permeability transition pore formation in the early minutes of reperfusion are critical to postconditioning's success. Basic Res Cardiol 2008;103:464-471.
108. Inserte J, Barba I, Hernando V, Abellan A, Ruiz-Meana M, Rodriguez-Sinovas A et al. Effect of acidic reperfusion on prolongation of intracellular acidosis and myocardial salvage. Cardiovasc Res 2008;77:782-790.
109. Argaud L, Gateau-Roesch O, Augeul L, Couture-Lepetit E, Loufouat J, Gomez L et al. Increased mitochondrial calcium coexists with decreased reperfusion injury in post-conditioned (but not preconditioned) hearts. Am J Physiol Heart Circ Physiol 2008;294: H386-H391.
110. Inserte J, Garcia-Dorado D, Hernando V, Soler-Soler J. Calpain-mediated impairment of Na+/K+-ATPase activity during early reperfusion contributes to cell death after myocardial ischemia. Circ Res 2005;97:465-473.
111. Chen M, Won DJ, Krajewski S, Gottlieb RA. Calpain and mitochondria in ischemia/reperfusion injury. J Biol Chem 2002;277:29181-29186.
112. Zhao X, Newcomb JK, Posmantur RM, Wang KK, Pike BR, Hayes RL. pH dependency of mu-calpain and m-calpain activity assayed by casein zymography following traumatic brain injury in the rat. Neurosci Lett 1998;247:53-57. (Pubitemid 28231335)
113. Hernando V, Inserte J, Satório CL, Parra V, Poncelas-Nozal M, Garć?a-Dorado D. Calpain translocation and activation as pharmacological targets during ischemia/reperfusion. J Mol Cell Cardiol 2010; doi:10.1016/j.yjmcc.2010.02.024. Published online ahead of print 6 March 2010.
114. Schulman D, Latchman DS, Yellon DM. Urocortin protects the heart from reperfu-sion injury via upregulaiton of p42/p44 MAPK signaling pathway. Am J Physiol Heart Circ Physiol 2002;283:H1481-H1488.
115. Hausenloy DJ, Yellon DM. New directions for protecting the heart against ischaemia/reperfusion injury: targeting the reperfusion injury salvage kinase (RISK)-pathway. Cardiovasc Res 2004;61:448-460.
116. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of 'Modified Reperfusion' protects the myocardium by activating the phosphatidyl-inositol 3-kinase-Akt pathway. Circ Res 2004;95:230-232.
117. Zhu M, Feng J, Lucchinetti E, Fischer G, Xu L, Pedrazzini T et al. Ischemic postcon-ditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. Cardiovasc Res 2006;72:152-162.
118. Sivaraman V, Mudalgiri NR, Di SC, Kolvekar S, Hayward M, Yap J et al. Postcondi-tioning protects human atrial muscle through the activation of the RISK pathway. Basic Res Cardiol 2007;102:453-459.
119. Juhaszova M, Zorov DB, Kim S-H, Pepe S, Fu Q, Fishbein KW et al. Glycogen synthase kinase-3ß mediates convergence of protection signaling to inhibit the mito-chondrial permeability transition pore. J Clin Invest 2004;113:1535-1549.
120. Das S, Wong R, Rajapakse N, Murphy E, Steenbergen C. Glycogen synthase kinase 3 inhibition slows mitochondrial adenine nucleotide transport and regulates voltage-dependent anion channel phosphorylation. Circ Res 2008;103:983-991.
121. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M. Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 2008;117:2761-2768.
122. Nishino Y, Webb IG, Davidson SM, Ahmed AI, Clark JE, Jacquet S et al. Glycogen synthase kinase-3 inactivation is not required for ischemic preconditioning or post-conditioning in the mouse. Circ Res 2008;103:307-314.
123. Michel MC, Li Y, Heusch G. Mitogen-activated protein kinases in the heart. Naunyn-Schmiedeberg's Arch Pharmacol 2001;363:245-266.
124. Behrends M, Schulz R, Post H, Alexandrov A, Belosjorow S, Michel MC et al. Inconsistent relation of MAPK activation to infarct size reduction by ischemic preconditioning in pigs. Am J Physiol Heart Circ Physiol 2000;279:H1111-H1119.
125. Schulz R, Belosjorow S, Gres P, Jansen J, Michel MC, Heusch G. p38 MAP kinase is a mediator of ischemic preconditioning in pigs. Cardiovasc Res 2002;55:690-700.
126. Bassi R, Heads R, Marber MS, Clark JE. Targeting p38-MAPK in the ischaemic heart: kill or cure? Curr Opin Pharmacol 2008;8:141-146.
127. Sun H-Y, Wang N-P, Halkos M, Kerendi F, Kin H, Guyton RA et al. Postconditioning attenuates cardiomyocyte apoptosis via inhibition of JNK and p38 mitogen-activated protein kinase signaling pathways. Apoptosis 2006;11:1583-1593.
128. Heusch G. No RISK, no cardioprotection? A critical perspective. Cardiovasc Res 2009;84:173-174.
129. Schwartz LM, Lagranha CJ. Ischemic postconditioning during reperfusion activates AKT and ERK without protecting against lethal myocardial ischemia/reperfusion injury in pigs. Am J Physiol Heart Circ Physiol 2006;290:H1011-H1018.
130. Darling CE, Jiang R, Maynard M, Whittaker P, Vinten-Johansen J, Przyklenk K. Post-conditioning via stuttering reperfusion limits myocardial infarct size in rabbit hearts: role of ERK1/2. Am J Physiol Heart Circ Physiol 2005;289:H1618-H1626.
131. Przyklenk K, Maynard M, Darling CE, Whittaker P. Aging mouse hearts are refractory to infarct size reduction with post-conditioning. J Am Coll Cardiol 2008;51: 1393-1398.
132. Skyschally A, van Caster P, Boengler K, Gres P, Musiolik J, Schilawa D et al. Ischemic postconditioning in pigs: no causal role for RISK activation. Circ Res 2009;104:15-18.
133. Musiolik J, van Caster P, Skyschally A, Boengler K, Gres P, Schulz R et al. Reduction of infarct size by gentle reperfusion without activation of reperfusion injury salvage kinases in pigs. Cardiovasc Res 2010;85:110-117.
134. Boengler K, Hilfiker-Kleiner D, Drexler H, Heusch G, Schulz R. The myocardial JAK/STAT pathway: from protection to failure. Pharmacol Therap 2008;120:172-185.
135. Lecour S. Activation of the protective survivor activating factor enhancement (SAFE) pathway against reperfusion injury: does it go beyond the RISK path? J Mol Cell Cardiol 2009;47:32-40.
136. Lacerda L, Somers S, Opie HL, Lecour S. Ischemic postconditioning protects against reperfusion injury via the SAFE pathway. Cardiovasc Res 2009;84:201-208.
137. Boengler K, Buechert A, Heinen Y, Roeskes C, Hilfiker-Kleiner D, Heusch G et al. Cardioprotection by ischemic postconditioning is lost in aged and STAT3-deficient mice. Circ Res 2008;102:131-135.
138. Goodman MD, Koch SE, Fuller-Bicer GA, Butler KL. Regulating RISK: a role for JAK-STAT signaling in postconditioning? Am J Physiol Heart Circ Physiol 2008;295: H1649-H1656.
139. Schulz R, Heusch G. Tumor necrosis factor-a and its receptors 1 and 2: Yin and Yang in myocardial infarction? Circulation 2009;119:1355-1357.
140. Lecour S, Suleman N, Deuchar GA, Somers S, Lacerda L, Huisamen B et al. Pharmacological preconditioning with tumor necrosis factor-a activates signal transducer and activator of transcription-3 at reperfusion without involving classic prosurvival kinases (Akt and extracellular signal-regulated kinase). Circulation 2005;112: 3911-3918.
141. Vessey DA, Kelley M, Li L, Huang Y, Zhou HZ, Zhu BQ et al. Role of sphingosine kinase activity in protection of heart against ischemia reperfusion injury. Med Sci Monit 2006;12:BR318-BR324.
142. Jin ZQ, Karliner JS, Vessey DA. Ischaemic postconditioning protects isolated mouse hearts against ischaemia/reperfusion injury via sphingosine kinase isoform-1 activation. Cardiovasc Res 2008;79:134-140.
143. Thielmann M, Dörge H, Martin C, Belosjorow S, Schwanke U, van de Sand A et al. Myocardial dysfunction with coronary microembolization: signal transduction through a sequence of nitric oxide, tumor necrosis factor-a and sphingosine. Circ Res 2002;90:807-813.
144. Penna C, Rastaldo R, Mancardi D, Raimondo S, Cappello S, Gattullo D et al. Post-conditioning induced cardioprotection requires signaling through a redox-sensitive mechanism, mitochondrial ATP-sensitive K+ channel and protein kinase C activation. Basic Res Cardiol 2006;101:180-189.
145. Zatta AJ, Kin H, Lee G, Wang N, Jiang R, Lust R et al. Infarct-sparing effect of myo-cardial postconditioning is dependent on protein kinase C signalling. Cardiovasc Res 2006;70:315-324.
146. Burley DS, Ferdinandy P, Baxter GF. Cyclic GMP and protein kinase-G in myocardial ischaemia/reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 2007;152:855-869.
147. Penna C, Cappello S, Mancardi D, Raimondo S, Rastaldo R, Gattullo D et al. Post-conditioning reduces infarct size in the isolated rat heart: role of coronary flow and pressure and the nitric oxide/cGMP pathway. Basic Res Cardiol 2006;101: 168-179.
148. Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T et al. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med 1995;182:367-377.
149. Bernardi P, Petronilli V, Di LF, Forte M. A mitochondrial perspective on cell death. Trends Biochem Sci 2001;26:112-117.
150. Heusch G, Boengler K, Schulz R. Inhibition of mitochondrial permeability transition pore opening: the holy grail of cardioprotection. Basic Res Cardiol 2010;105: 151-154.
151. Di Lisa F, Bernardi P. A CaPful of mechanisms regulating the mitochondrial permeability transition. J Mol Cell Cardiol 2009;46:775-780.
152. Rasola A, Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis 2007;12:815-833.
153. Baines CP. The mitochondrial permeability transition pore and ischemia/reperfusion injury. Basic Res Cardiol 2009;104:181-188.
154. Basso E, Fante L, Fowlkes J, Petronilli V, Forte MA, Bernardi P. Properties of the permeability transition pore in mitochondria devoid of Cyclophilin D. J Biol Chem 2005; 280:18558-18561.
155. Halestrap AP, Pasdois P. The role of the mitochondrial permeability transition pore in heart disease. Biochim Biophys Acta 2009;1787:1402-1415.
156. Di LF, Kaludercic N, Carpi A, Menabo R, Giorgio M. Mitochondrial pathways for ROS formation and myocardial injury: the relevance of p66(Shc) and monoamine oxidase. Basic Res Cardiol 2009;104:131-139.
157. Argaud L, Gateau-Roesch O, Raisky O, Loufouat J, Robert D, Ovize M. Postcondi-tioning inhibits mitochondrial permeability transition. Circulation 2005;111:194-197. (Pubitemid 40139731)
158. Hausenloy DJ, Yellon DM, Mani-Babu S, Duchen MR. Preconditioning protects by inhibiting the mitochondrial permeability transition. Am J Physiol Heart Circ Physiol 2004;287:H841-H849.
159. Hausenloy DJ, Yellon DM. Preconditioning and postconditioning: united at reperfu-sion. Pharmacol Ther 2007;116:173-191.
160. Javadov SA, Clarke S, Das M, Griffiths EJ, Lim KH, Halestrap AP. Ischaemic preconditioning inhibits opening of mitochondrial permeability transition pores in the reperfused rat heart. J Physiol 2003;549:513-524.
161. Halestrap AP, Clarke SJ, Khaliulin I. The role of mitochondria in protection of the heart by preconditioning. Biochim Biophys Acta 2007;1767:1007-1031.
162. Argaud L, Gateau-Roesch O, Muntean D, Chalabreysse L, Loufouat J, Robert D et al. Specific inhibition of the mitochondrial permeability transition prevents lethal reper-fusion injury. J Mol Cell Cardiol 2005;38:367-374. (Pubitemid 40215206)
163. Griffiths EJ, Halestrap AP. Protection by Cyclosporin A of ischemia/reperfusion-induced damage in isolated rat hearts. J Mol Cell Cardiol 1993;25: 1461-1469.
164. Griffiths EJ, Halestrap AP. Mitochondrial non-specific pores remain closed during cardiac ischaemia, but open upon reperfusion. Biochem J 1995;307:93-98.
165. Di Lisa F, Bernardi P. Mitochondria and ischemia/reperfusion injury of the heart: Fixing a hole. Cardiovasc Res 2006;70:191-199.
166. Piot C, Croisille P, Staat P, Thibault H, Rioufol G, Mewton N et al. Effect of cyclos-porine on reperfusion injury in acute myocardial infarction. N Engl J Med 2008;359: 473-481.
167. Steenbergen C, Das S, Su J, Wong R, Murphy E. Cardioprotection and altered mito-chondrial adenine nucleotide transport. Basic Res Cardiol 2009;104:149-156.
168. Costa AD, Jakob R, Costa CL, Andrukhiv K, West IC, Garlid KD. The mechanism by which the mitochondrial ATP-sensitive K+ channel opening and H2O2 inhibit the mitochondrial permeability transition. J Biol Chem 2006;281:20801-20808.
169. Boengler K, Dodoni G, Ruiz-Meana M, Cabestrero A, Rodriguez-Sinovas A, Garcia-Dorado D et al. Connexin 43 in cardiomyocyte mitochondria and its increase by ischemic preconditioning. Cardiovasc Res 2005;67:234-244.
170. Heinzel FR, Luo Y, Li X, Boengler K, Buechert A, Garća-Dorado D et al. Impairment of diazoxide-induced formation of reactive oxygen species and loss of cardioprotec-tion in connexin 43 deficient mice. Circ Res 2005;97:583-586.
171. Heusch G, Büchert A, Feldhaus S, Schulz R. No loss of cardioprotection by postcon-ditioning in connexin 43-deficient mice. Basic Res Cardiol 2006;101:354-356.
172. Crisostomo PR, Wang M, Wairiuko GM, Terrell AM, Meldrum DR. Postconditioning in females depends on injury severity. J Surg Res 2006;134:342-347.
173. Dow J, Kloner RA. Postconditioning does not reduce myocardial infarct size in an in vivo regional ischemia rodent model. J Cardiovasc Pharmacol Ther 2007;12:153-163.
174. Boengler K, Schulz R, Heusch G. Loss of cardioprotection with ageing. Cardiovasc Res 2009;83:247-261.
175. Yin Z, Gao H, Wang H, Li L, Di C, Luan R et al. Ischemic postconditioning protects both adult and aged Sprague Dawley rat hearts from ischemia/reperfusion injury through the PI3-K/Akt and GSK-3beta pathway. Clin Exp Pharmacol Physiol 2009; 36:756-763.
176. Ferdinandy P, Schulz R, Baxter GF. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007;59:418-458.
177. Ferdinandy P. Myocardial ischaemia/reperfusion injury and preconditioning: effects of hypercholesterolaemia/hyperlipidaemia. Br J Pharmacol 2003;138:283-285. (Pubitemid 36188588)
178. Iliodromitis EK, Zoga A, Vrettou A, Andreadou I, Paraskevaidis IA, Kaklamanis L et al. The effectiveness of postconditioning and preconditioning on infarct size in hyperch-olesterolemic and normal anesthetized rabbits. Atherosclerosis 2006;188:356-362.
179. ′-cyclic monophosphate/protein kinase G-dependent cardioprotection in rats. Br J Pharmacol 2009;158:1495-1502.
180. Wagner C, Kloeting I, Strasser RH, Weinbrenner C. Cardioprotection by postcon-ditioning is lost in WOKW rats with metabolic syndrome: role of glycogen synthase kinase 3beta. J Cardiovasc Pharmacol 2008;52:430-437.
181. Bouhidel O, Pons S, Souktani R, Zini R, Berdeaux A, Ghaleh B. Myocardial ischemic postconditioning against ischemia/reperfusion is impaired in ob/ob mice. Am J Physiol Heart Circ Physiol 2008;295:H1580-H1586.
182. Huhn R, Heinen A, Hollmann MW, Schlack W, Preckel B, Weber NC. Cyclosporine A administered during reperfusion fails to restore cardioprotection in prediabetic Zucker obese rats in vivo. Nutr Metab Cardiovasc Dis 2009; doi:10.1016/j.numecd.2009.06.010. Published online ahead of print 9 October 2009.
183. Penna C, Tullio F, Moro F, Folino A, Merlino A, Pagliaro P. Effects of a protocol of ischemic postconditioning and/or captopril in hearts of normotensive and hypertensive rats. Basic Res Cardiol 2010;105:181-192.
184. Feng J, Fischer G, Lucchinetti E, Zhu M, Bestmann L, Jegger D et al. Infarct-remodeled myocardium is receptive to protection by isoflurane postcondi-tioning: role of protein kinase B/Akt signaling. Anesthesiology 2006;104:1004-1014.
185. Lange M, Redel A, Lotz C, Smul TM, Blomeyer C, Frank A et al. Desflurane-induced postconditioning is mediated by beta-adrenergic signaling: role of beta 1-and beta 2-adrenergic receptors, protein kinase A, and calcium/calmodulin-dependent protein kinase II. Anesthesiology 2009;110:516-528.
186. Oikawa M, Yaoita H, Watanabe K, Maruyama Y. Attenuation of cardioprotective effect by postconditioning in coronary stenosed rat heart and its restoration by car-vedilol. Circ J 2008;72:2081-2086.
187. Heusch G, Skyschally A, Gres P, van Caster P, Schilawa D, Schulz R. Improvement of regional myocardial blood flow and function and reduction of infarct size with ivab-radine\protection beyond heart rate reduction. Eur Heart J 2008;29:2265-2275.
188. Kocsis GF, Pipis J, Fekete V, Kovacs-Simon A, Odendaal L, Molnar E et al. Lovastatin interferes with the infarct size-limiting effect of ischemic preconditioning and post-conditioning in rat hearts. Am J Physiol Heart Circ Physiol 2008;294:H2406-H2409.
189. Obal D, Dettwiler S, Favoccia C, Scharbatke H, Preckel B, Schlack W. The influence of mitochondrial KATP-channels in the cardioprotection of preconditioning and postconditioning by sevoflurane in the rat in vivo. Anesth Analg 2005;101: 1252-1260.
190. Staat P, Rioufol G, Piot C, Cottin Y, Cung TT, L'Huillier I et al. Postconditioning the human heart. Circulation 2005;112:2143-2148.
191. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G et al. Long-term benefit of postconditioning. Circulation 2008;117:1037-1044.
192. Darling CE, Solari PB, Smith CS, Furman MI, Przyklenk K. 'Postconditioning' the human heart: multiple balloon inflations during primary angioplasty may confer car-dioprotection. Basic Res Cardiol 2007;102:274-278.
193. Hori M, Kitakaze M, Sato S, Takashima S, Iwakura K, Inoue A et al. Staged reperfusion attenuates myocardial stunning in dogs. Role of transient acidosis during early reper-fusion. Circulation 1991;84:2135-2145.
194. Takeo S, Liu J-X, Tanonaka K, Nasa Y, Yabe K, Tanahashi H et al. Reperfusion at reduced flow rates enhances postischemic contractile recovery of perfused heart. Am J Physiol 1995;268:H2384-H2395.
195. Loukogeorgakis SP, Williams R, Panagiotidou AT, Kolvekar SK, Donald A, Cole TJ et al. Transient limb ischemia induces remote preconditioning and remote postcon-ditioning in humans by a KATP channel dependent mechanism. Circulation 2007;116: 1386-1395.
196. Botker HE, Kharbanda RK, Schmidt MR, Bottcher M, Kaltoft AK, Terkelsen CJ et al. Prehospital remote ischaemic conditioning increases myocardial salvage in acute myocardial infarction. Lancet 2010;375:1090-1099.
197. Mahaffey KW, Puma JA, Barbagelata A, DiCarli MF, Leesar MA, Browne KF et al. Adenosine as an adjunct thrombolytic therapy for acute myocardial infarction. J Am Coll Cardiol 1999;34:1711-1720.
198. Kopecky SL, Aviles RJ, Bell MR, Lobl JK, Tipping D, Frommell G et al. A randomized, double-blinded, placebo-controlled, dose-ranging study measuring the effect of an adenosine agonist on infarct size reduction in patients undergoing primary percutaneous transluminal coronary angioplasty: the ADMIRE (AmP579 Delivery for Myo-cardial Infarction REduction) study. Am Heart J 2003;146:146-152.
199. Ross AM, Gibbons R-J, Stone GW, Kloner RA, Alexander RW. A randomized, double-blinded placebo-controlled multicenter trial of adenosine as an adjunct to reperfusion in the treatment of acute myocardial infarction (AMISTAD-II). J Am Coll Cardiol 2005;45:1775-1780.
200. Kloner RA, Forman MB, Gibbons RJ, Ross AM, Alexander RW, Stone GW. Impact of time to therapy and reperfusion modality on the efficacy of adenosine in acute myo-cardial infarction: the AMISTAD-2 trial. Eur Heart J 2006;27:2400-2405.
201. Garća-Dorado D, Agullo L, Sartório CL, Ruiz-Meana M. Myocardial protection against reperfusion injury: the cGMP pathway. Thromb Haemost. 2009. 101. 635-642.
202. Kitakaze M, Asakura M, Kim J, Shintani Y, Asanuma H, Hamasaki T et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet 2007;370: 1483-1493.
203. Burley DS, Hamid SA, Baxter GF. Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail Rev 2007;12:279-291.
204. Hausenloy DJ, Maddock HL, Baxter GF, Yellon DM. Inhibiting mitochondrial permeability transition pore opening: a new paradigm for myocardial preconditioning? Cardiovasc Res 2002;55:534-543.
205. Downey JM, Cohen MV. Why do we still not have cardioprotective drugs? Circ J 2009; 73:1171-1177.
206. Aletras AH, Tilak GS, Natanzon A, Hsu LY, Gonzalez FM, Hoyt RF Jr et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation 2006;113:1865-1870.
207. Sanz E, Dorado DG, Oliveras J, Barrabés JA, Gonzalez MA, Ruiz-Meana M et al. Dissociation between anti-infarct effect and anti-edema effect of ischemic preconditioning. Am J Physiol Heart Circ Physiol 1995;37:H233-H241.
208. Garcia-Dorado D, Oliveras J. Myocardial edema: a preventable cause of reperfusion injury. Cardiovasc Res 1993;27:1555-1563.
209. Garcia-Dorado D, Piper HM. Postconditioning: Reperfusion of 'reperfusion injury' after hibernation. Cardiovasc Res 2006;69:1-3.
210. Laskey WK. Brief repetitive balloon occlusions enhance reperfusion during percutaneous coronary intervention for acute myocardial infarction: A Pilot Study. Cathet Cardiovasc Intervent 2005;65:361-367.
211. Ma X, Zhang X, Li C, Luo M. Effect of postconditioning on coronary blood flow velocity and endothelial function and LV recovery after myocardial infarction. J Interv Cardiol 2006;19:367-375. (Pubitemid 44511065)
212. Yang XC, Liu Y, Wang LF, Cui L, Wang T, Ge YG et al. Reduction in myocardial infarct size by postconditioning in patients after percutaneous coronary intervention. J Invasive Cardiol 2007;19:424-430.
213. Laskey WK, Yoon S, Calzada N, Ricciardi MJ. Concordant improvements in coronary flow reserve and ST-segment resolution during percutaneous coronary intervention for acute myocardial infarction: a benefit of postconditioning. Catheter Cardiovasc Interv 2008;72:212-220.
214. Zhao WS, Xu L, Wang LF, Zhang L, Zhang ZY, Liu Y et al. A 60-s postconditioning protocol by percutaneous coronary intervention inhibits myocardial apoptosis in patients with acute myocardial infarction. Apoptosis 2009;14:1204-1211.
215. Lonborg J, Kelbaek H, Vejlstrup N, Jorgensen E, Helqvist S, Saunamaki K et al. Car-dioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. Circ Cardio-vasc Interv 2010;3:34-41.
216. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004;109:962-965.
217. Mehta SR, Yusuf S, Diaz R, Zhu J, Pais P, Xavier D et al. Effectof glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005;293:437-446.
218. Bates E, Bode C, Costa M, Gibson CM, Granger C, Green C et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 2008;117:886-896.
219. Ferrario M, Arbustini E, Massa M, Rosti V, Marziliano N, Raineri C et al. High-dose erythropoietin in patients with acute myocardial infarction: A pilot, randomised, placebo-controlled study. Int J Cardiol 2009; doi:10.1016/j.ijcard. 2009.10.028. Published online ahead of print 10 November 2009.
220. Suh JW, Chung WY, Kim YS, Kim KI, Jeon EJ, Cho YS et al. The effect of intravenous administration of erythropoietin on the infarct size in primary percutaneous coronary intervention. Int J Cardiol 2010; doi:10.1016/j.ijcard. 2010.02.002. Published online ahead of print 3 March 2010.
221. Kim J-S, Kim J, Choi D, Lee CJ, Lee SH, Ko Y-G et al. Efficacy of high-dose atorvas-tatin loading before primary percutaneous coronary intervention in ST-segment elevation myocardial infarction. JACC Cardiovasc Interv 2010;3:332-339.